Global Multiple Myeloma Therapeutics Market and Forecast to 2030

1. Global Multiple Myeloma Therapeutics Market Analysis 2024-2030 Comprehensive Market Overview | Growth Drivers | Segmentation | Regional Insights | Future Outlook Prepared by Apelo Consulting 1 Global Multiple Myeloma Therapeutics Market Analysis Apelo Consulting

2. Executive Summary Market size: USD 27,013M (2024) → USD 39,084M (2030) CAGR (2024–2030): ≈ 6.3% Key Growth Drivers: Rising prevalence and aging population Improved diagnostic criteria Adoption of targeted therapies Increasing awareness and early detection 2024 Market Leaders: Disease: Active Multiple Myeloma Treatment: Targeted Therapy Administration: Oral Route End User: Hospitals Region: North America Apelo Consulting | Page 2

3. Market Overview & Disease Profile Multiple Myeloma: Cancer characterized by uncontrolled proliferation of clonal plasma cells, leading to organ dysfunction and eventually death Treatment Landscape: Chemotherapy: Targets rapidly dividing cancer cells throughout the body Targeted Therapy: Proteasome monoclonal antibodies - less toxic alternatives Immunomodulating Agents: Thalidomide, lenalidomide, pomalidomide Radiation Therapy: Manages localized bone lesions, alleviates pain Stem Cell Transplantation: For eligible patients, after induction inhibitors and New cases expected in the U.S. (2025) Source: National Cancer Institute 36,110 Market Focus: Early diagnosis and tailored treatments are crucial for enhancing patient outcomes and increasing survival rates Apelo Consulting | Page 3

4. Segmentation by Disease Type Active Multiple Myeloma Market position: Dominant segment Characteristics: treatment Growth drivers: combination therapies Treatment focus: remission periods Symptomatic, requires immediate Advancements in supportive care, Disease management, extending Smoldering Multiple Myeloma (SMM) Market position: Smaller but growing segment Characteristics: Asymptomatic, higher levels of abnormal plasma cells Growth trend: Early detection increasing due to improved diagnostics Treatment approach: Monitoring with timely intervention before symptom development Early intervention in SMM cases has shown promising results in delaying progression to active MM, driving increased focus on detection technologies and preventive therapies. Apelo Consulting | Page 4

5. Treatment Landscape Segmentation Targeted Therapy: Dominant segment in 2024, offering more effective and less toxic alternatives to traditional chemotherapy Chemotherapy: Maintained over 25% market share in 2024, remains foundational for systemic treatment Immunomodulating frontline and maintenance therapy, known for oral convenience Agents: Core components for Stem Cell Transplantation: Critical for eligible patients, typically performed after induction therapy Radiation Therapy: Focused on symptom management for bone lesions rather than primary treatment Others: complement mainstream therapies Supportive care and adjunct approaches Apelo Consulting | Page 5

6. Route of Administration & End User Route of Administration End User Oral Route: Dominant; non-invasive approach offering better adherence, convenience, and reduced hospital visits Parenteral Route: advanced/refractory cases; allows precise dosing and clinical monitoring Hospitals: Leading segment; equipped with advanced infrastructure for complex treatment protocols Clinics: Provide specialized outpatient care in more accessible settings Homecare: Growing segment for maintenance therapies and oral regimens Critical for *Oral administration continues to gain preference due to improved patient compliance and convenience factors Apelo Consulting | Page 6

7. Regional Market Analysis North America: Dominant market position Advanced healthcare prevalence, rapid integration of innovative therapies infrastructure, high disease Europe: Second largest market Strong uptake of targeted therapies and personalized medicine across Germany, UK, France, and Italy Asia Pacific: Emerging market Increasing healthcare expenditure, rising awareness, and improving healthcare infrastructure Latin America: Developing market Expanding access to novel therapies and treatment options Middle East & Africa: Growth potential Improving care pathways and increasing investment in healthcare Apelo Consulting | Page 7

8. Key Market Players Leading pharmaceutical companies and research institutions in the Multiple Myeloma therapeutics landscape Apelo Consulting | Page 8

9. Market Dynamics: Drivers & Challenges Growth Drivers Challenges Rising Prevalence & Aging Demographics Increasing incidence rates globally, particularly in aging populations with 36,110 new US cases expected in 2025 High Treatment Costs & Access Disparities Novel therapies and associated with substantial costs, creating barriers to access particularly in developing regions combination regimens Improved Diagnostic Criteria & Earlier Detection Enhanced screening methods and diagnostic technologies enabling earlier disease identification, especially for SMM Complex Disease Management Requirement for specialized multidisciplinary care teams and individualized treatment approaches Treatment Resistance & Relapse Development of resistance to therapy over time, necessitating multiple lines of treatment and ongoing research Advancements in Targeted Therapies Revolutionary treatment proteasome inhibitors and monoclonal antibodies with higher efficacy and lower toxicity options including Need for Specialized Healthcare Infrastructure Advanced treatment sophisticated healthcare systems and trained professionals Growing Awareness & Screening Practices Increased knowledge among healthcare providers and patients leading to improved care pathways and treatment adherence modalities require Apelo Consulting | Page 9

10. Key Takeaways & Market Outlook Market Growth: USD 27.0B (2024) to USD 39.1B (2030); ~6.3% CAGR driven by increasing prevalence and advanced therapies Disease Segments: Active MM remains dominant; Smoldering MM detection rising with improved diagnostic criteria and earlier intervention Treatment Landscape: Targeted therapies and IMiDs anchor treatment growth; chemotherapy retains significant role (25%+ market share) Administration & Settings: Oral route dominates administration; hospital settings lead utilization patterns due to infrastructure advantages Regional Dynamics: North America leads market; Asia Pacific offers highest growth runway with increasing healthcare expenditure Future Innovation: Novel molecular targets, combination regimens, and personalized medicine approaches will shape market evolution Continued innovation in targeted therapies paired with broader market access will be critical success factors for stakeholders in this growing therapeutic area. Apelo Consulting | Page 10

11. THANK YOU www.apeloconsulting.com